Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 9/20 | 0.59 |
| ▸ | TNF | P01375 | 5/20 | 0.59 |
| ▸ | IL1B | P01584 | 4/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24816666 | 0.89 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL31204288 | 0.84 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL30992940 | 0.82 | CRBN (0.65) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL29094750 | 0.82 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL29094759 | 0.82 | CRBN (0.67) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL30993501 | 0.82 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL24967103 | 0.82 | CRBN (0.72) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL30993083 | 0.81 | CRBN (0.63) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL30993055 | 0.81 | CRBN (0.63) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL31204551 | 0.81 | DDB1 (0.66) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-02 | — | — | US | disclosed |
| WO-2024259216-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002473-A1 | QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF | EGFR, ERBB2, ERBB4 | CRBN 2544/4885IKZF3 4290/4885TNF 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.